CA2867118A1 - Detection precoce d'une reponse au traitement de la tuberculose - Google Patents

Detection precoce d'une reponse au traitement de la tuberculose Download PDF

Info

Publication number
CA2867118A1
CA2867118A1 CA2867118A CA2867118A CA2867118A1 CA 2867118 A1 CA2867118 A1 CA 2867118A1 CA 2867118 A CA2867118 A CA 2867118A CA 2867118 A CA2867118 A CA 2867118A CA 2867118 A1 CA2867118 A1 CA 2867118A1
Authority
CA
Canada
Prior art keywords
genes
mrna
homo sapiens
gene expression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2867118A
Other languages
English (en)
Inventor
Anne O'garra
Chloe BLOOM
Matthew Paul Reddoch Berry
Robert Wilkinson
Jacques F. Banchereau
Damien Chaussabel
Maria Virginia Pascual
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Imperial College Healthcare NHS Trust
Baylor Research Institute
Original Assignee
Medical Research Council
Imperial College Healthcare NHS Trust
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Imperial College Healthcare NHS Trust, Baylor Research Institute filed Critical Medical Research Council
Publication of CA2867118A1 publication Critical patent/CA2867118A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2867118A 2012-03-13 2013-03-13 Detection precoce d'une reponse au traitement de la tuberculose Abandoned CA2867118A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610121P 2012-03-13 2012-03-13
US61/610,121 2012-03-13
PCT/US2013/030986 WO2013138497A1 (fr) 2012-03-13 2013-03-13 Détection précoce d'une réponse au traitement de la tuberculose

Publications (1)

Publication Number Publication Date
CA2867118A1 true CA2867118A1 (fr) 2013-09-19

Family

ID=49161779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867118A Abandoned CA2867118A1 (fr) 2012-03-13 2013-03-13 Detection precoce d'une reponse au traitement de la tuberculose

Country Status (4)

Country Link
US (1) US20150133469A1 (fr)
EP (1) EP2825671A4 (fr)
CA (1) CA2867118A1 (fr)
WO (1) WO2013138497A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2953524B1 (fr) 2013-02-06 2018-08-01 Freenome Holdings Inc. Systèmes et procédés pour la détection de maladie précoce et la surveillance de maladie en temps réel
EP3097202B1 (fr) * 2014-01-21 2018-10-31 Morehouse School of Medicine Dépistage d'infections et de maladies médié par des exosomes
CN104846096B (zh) * 2015-05-21 2017-06-30 中国人民解放军军事医学科学院微生物流行病研究所 CD40LG基因rs3092923多态性在检测中国人男性肺结核中的应用
KR20170027258A (ko) * 2015-09-01 2017-03-09 제이더블유바이오사이언스 주식회사 트립토파닐 티알엔에이 합성효소를 이용한 패혈증의 진단용 조성물과 진단 마커 검출 방법
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CN106680411B (zh) * 2017-03-20 2018-10-09 汉氏联合（天津）干细胞研究院有限公司 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法
CN107190075A (zh) * 2017-06-27 2017-09-22 深圳优圣康医学检验所有限公司 用于mRNA检测的试剂及用途
GB2583386B (en) * 2019-02-18 2023-11-01 Int Centre For Genetic Engineering And Biotechnology Method for predicting treatment response for first line of tuberculosis drug regime
WO2021070107A1 (fr) * 2019-10-08 2021-04-15 Stellenbosch University Polypeptides ifit et utilisations pour le traitement d'une infection tuberculeuse
CN112143793A (zh) * 2020-09-30 2020-12-29 中国医学科学院病原生物学研究所 Odf3b作为结核病诊断分子标识的用途
CN112684183B (zh) * 2020-12-20 2022-09-02 中国医学科学院病原生物学研究所 一种多抗原蛋白组合应用于肺结核的鉴别与诊断

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054072A2 (fr) * 2001-01-08 2002-07-11 Isis Innovation Limited Essai biologique permettant d'evaluer l'efficacite du traitement d'une infection mycobacterienne
AU2003241055A1 (en) * 2002-06-20 2004-01-06 Glaxo Group Limited Surrogate markers for the determination of the disease status of an individual infected by mycobacterium tuberculosis
US20060177837A1 (en) * 2004-08-13 2006-08-10 Ivan Borozan Systems and methods for identifying diagnostic indicators
JP2011526152A (ja) * 2008-06-25 2011-10-06 ベイラー リサーチ インスティテュート マイコバクテリウム・ツベルクローシス感染症の血液転写サイン
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
CA2743211A1 (fr) * 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Procedes et systemes d'utilisation d'exosomes pour determiner des phenotypes
AU2011223789A1 (en) * 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics

Also Published As

Publication number Publication date
EP2825671A1 (fr) 2015-01-21
US20150133469A1 (en) 2015-05-14
EP2825671A4 (fr) 2015-08-26
WO2013138497A1 (fr) 2013-09-19

Similar Documents

Publication Publication Date Title
US20150133469A1 (en) Early detection of tuberculosis treatment response
AU2010325179B2 (en) Blood transcriptional signature of active versus latent Mycobacterium tuberculosis infection
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
KR20110036590A (ko) 결핵균 감염의 혈액 전사 시그너처
US20120277999A1 (en) Methods, kits and arrays for screening for, predicting and identifying donors for hematopoietic cell transplantation, and predicting risk of hematopoietic cell transplant (hct) to induce graft vs. host disease (gvhd)
EP3411501A1 (fr) Méthodes biologiques de diagnostic de tuberculose active ou de détermination du risque d'une infection latente par la tuberculose évoluant en tuberculose active et matériaux utilisables dans ces méthodes
AU2017293417A1 (en) Biomarkers for inflammatory bowel disease
US10106855B2 (en) Genetic assay to determine prognosis in Polycythemia Vera patients
EP3146076A2 (fr) Profils d'expression génique associés au rejet de greffe du rein subclinique
EP2521730A1 (fr) Biomarqueurs géniques de la fonction pulmonaire
US20070134690A1 (en) Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
AU2021221905A1 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2012150276A1 (fr) Signatures de l'expression génétique du cancer du poumon, détectées au moyen de sang
US11525161B2 (en) Methods of distinguishing ischemic stroke from intracerebral hemorrhage
AU2018335382A1 (en) Novel cell line and uses thereof
US20110281750A1 (en) Identifying High Risk Clinically Isolated Syndrome Patients
Verner et al. Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation
US20130345086A1 (en) Cd4+ t-cell gene signature for rheumatoid arthritis (ra)
AU2015203028A1 (en) Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
WO2012162594A1 (fr) Procédés de détermination de l'efficacité d'une vaccination, dispositifs et compositions apparentés
Class et al. Patent application title: Genetic Assay to Determine Prognosis in Polycythemia Vera Patients Inventors: Jerry L. Spivak (Baltimore, MD, US) Michael Ochs (Oreland, PA, US) Michael Considine (Belair, MD, US) Donna Rowley (Beltsville, MD, US) Alison R. Moliterno (Baltimore, MD, US)
NZ750396B2 (en) Biomarkers for inflammatory bowel disease
Morgun et al. UltraRapid Communication

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180313